Twist Bioscience reported record revenue of $88.7 million for the first quarter of fiscal 2025, marking an increase of 24% from the same period in the prior year. This quarter also marked the company's eighth consecutive quarter of sequential revenue growth. Gross margin improved to 48.3%, up from 40.5% in the first quarter of fiscal 2024.

CEO Emily M. Leproust emphasized the company’s progress toward achieving adjusted EBITDA breakeven, noting multiple growth opportunities expected to drive sustainable expansion. The company expects total revenue for fiscal 2025 to range between $372 million and $379 million, reflecting year-over-year growth of 19% to 21%. Gross margin is projected to exceed 50% in the fourth quarter of fiscal 2025.

Revenue from synthetic biology (SynBio) grew 28% year-over-year to $34.4 million, while next-generation sequencing (NGS) revenue increased 23% to $48.6 million. Biopharma revenue also saw a modest rise, reaching $5.7 million.

Net loss for the quarter was $31.6 million, or $0.53 per share, compared to a loss of $43.0 million, or $0.75 per share, in the same quarter last year. Adjusted EBITDA improved to negative $16.3 million from negative $27.8 million in the prior year.

For the second quarter of fiscal 2025, Twist anticipates revenue between $91 million and $93 million, with continued sequential improvements in adjusted EBITDA.

The company remains focused on advancing its synthetic DNA platform for applications in healthcare, industrial chemicals, agriculture, and academic research. It also continues to develop longer-term initiatives, such as digital data storage in DNA and biologics drug discovery.

Twist will hold a conference call to discuss its financial results and business updates, with a webcast available for investors.